Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis

Introduction: In Chinese patients with NSCLC, prevalence of EGFR-mutated (EGFRm) disease is high. In the global phase 3 ADAURA study (NCT02511106), adjuvant osimertinib was found to have a statistically significant and clinically meaningful improvement in disease-free survival (DFS) versus placebo i...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jie Wang, MD, PhD, Yi-Long Wu, MD, Shun Lu, MD, PhD, Qun Wang, MD, Shanqing Li, MD, Wen-Zhao Zhong, MD, PhD, Qiming Wang, MD, Wei Li, MD, PhD, Buhai Wang, MD, Jun Chen, MD, Ying Cheng, MD, Hongbing Duan, MD, Gaofeng Li, MD, Li Shan, MD, Yangbo Liu, MS, Jing Liu, MD, Xiangning Huang, PhD, Ana Bolanos, MD, Jie He, MD, PhD
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-02-01
Col·lecció:	JTO Clinical and Research Reports
Matèries:	Adjuvant Osimertinib EGFR NSCLC China
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666364323001649
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!